Department of Veterinary Pharmacology, Graduate school of Agriculture and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan.
Eur J Pharmacol. 2011 Jun 25;660(2-3):375-80. doi: 10.1016/j.ejphar.2011.03.032. Epub 2011 Apr 2.
Prostaglandin E2 (PGE2) is one major prostanoid produced under inflammatory situation. Although PGE2 is known to induce vascular contraction, its detailed mechanism remains unknown. In the present study, we investigated the signaling pathway underlying PGE2-induced smooth muscle contraction in rat mesenteric artery. PGE2 (0.3-30 μM) concentration-dependently caused contraction in endothelium-denuded artery. RT-PCR showed that this artery expresses mRNAs for all four prostanoid EP receptors (prostanoid EP1-4). Among selective agonists for PGE2 receptors, only a prostanoid EP3 receptor agonist, ONO-AE-248 (0.3-30 μM) induced contraction. Consistently, pretreatment with a prostanoid EP3 antagonist (L-798106, 1 μM) significantly but not completely inhibited the PGE2-induced contraction. Interestingly, pretreatment with a prostanoid FP antagonist (AL8810, 1 μM) or a TP antagonist (SQ29548, 10 nM) also partially inhibited the PGE2-induced contraction. Since ONO-AE-248 (10 μM) did not influence intracellular Ca2+ concentration in mesenteric artery, we next examined the involvement of Ca2+-independent contractile pathway including PKCs and ROCK in prostanoid EP3-mediated contraction. Pretreatment with bisindolyl-maleimide I (a general PKC inhibitor, 1 μM), Ro-31-8425 (a conventional PKC and PKCε inhibitor, 1 μM), rottlerin (a selective PKCδ inhibitor, 1 μM) and Y-27632 (a ROCK inhibitor, 1 μM) but not Go 6976 (a conventional PKC inhibitor, 1 μM) attenuated 10 μM ONO-AE-248-induced vascular contraction. In western blot analysis, we confirmed that the treatment with ONO-AE-248 (10 μM, 30 min) phosphorylated PKCδ (Thr505) and PKCε (Ser729). These results suggest that PGE2 induces vascular smooth muscle contraction via prostanoid EP3, FP and TP receptors in rat mesenteric artery. Prostanoid EP3-mediated contraction is ascribed to Ca2+-independent contractile pathway including PKCδ, ε and ROCK.
前列腺素 E2(PGE2)是炎症情况下产生的主要前列腺素之一。尽管已知 PGE2 可引起血管收缩,但具体机制尚不清楚。在本研究中,我们研究了 PGE2 诱导大鼠肠系膜动脉平滑肌收缩的信号通路。PGE2(0.3-30 μM)浓度依赖性地引起去内皮动脉收缩。RT-PCR 显示该动脉表达所有四种前列腺素 EP 受体(前列腺素 EP1-4)的 mRNA。在 PGE2 受体的选择性激动剂中,只有前列腺素 EP3 受体激动剂 ONO-AE-248(0.3-30 μM)引起收缩。一致地,前列腺素 EP3 拮抗剂(L-798106,1 μM)预处理显著但不完全抑制 PGE2 诱导的收缩。有趣的是,前列腺素 FP 拮抗剂(AL8810,1 μM)或 TP 拮抗剂(SQ29548,10 nM)预处理也部分抑制了 PGE2 诱导的收缩。由于 ONO-AE-248(10 μM)不影响肠系膜动脉中的细胞内 Ca2+浓度,因此我们接下来检查了包括蛋白激酶 C(PKC)和 ROCK 在内的 Ca2+-非依赖性收缩途径在前列腺素 EP3 介导的收缩中的参与。预处理 bisindolyl-maleimide I(一种通用 PKC 抑制剂,1 μM)、Ro-31-8425(一种常规 PKC 和 PKCε抑制剂,1 μM)、rottlerin(一种选择性 PKCδ抑制剂,1 μM)和 Y-27632(一种 ROCK 抑制剂,1 μM)但不是 Go 6976(一种常规 PKC 抑制剂,1 μM)减弱了 10 μM ONO-AE-248 诱导的血管收缩。在 Western blot 分析中,我们证实 ONO-AE-248(10 μM,30 分钟)处理可使 PKCδ(Thr505)和 PKCε(Ser729)磷酸化。这些结果表明,PGE2 通过大鼠肠系膜动脉中的前列腺素 EP3、FP 和 TP 受体诱导血管平滑肌收缩。前列腺素 EP3 介导的收缩归因于包括 PKCδ、ε 和 ROCK 在内的 Ca2+-非依赖性收缩途径。